SA112340005B1 - صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa - Google Patents

صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa

Info

Publication number
SA112340005B1
SA112340005B1 SA112340005A SA112340005A SA112340005B1 SA 112340005 B1 SA112340005 B1 SA 112340005B1 SA 112340005 A SA112340005 A SA 112340005A SA 112340005 A SA112340005 A SA 112340005A SA 112340005 B1 SA112340005 B1 SA 112340005B1
Authority
SA
Saudi Arabia
Prior art keywords
formulation
omega
fatty acid
present
hmg
Prior art date
Application number
SA112340005A
Other languages
English (en)
Inventor
جين يون إيون
هو كيم جاي
هيون بارك جاي
سو وو جونج
شيول كيم جين
إل كيم يونج
Original Assignee
هانمي فارم . كو . ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by هانمي فارم . كو . ليمتد. filed Critical هانمي فارم . كو . ليمتد.
Publication of SA112340005B1 publication Critical patent/SA112340005B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

يتعلق الاختراع الحالي بصيغة معقدة عن طريق الفم oral مشتملة على : omega-3 fatty acid أو مشتقاته مكبسلة في كبسولة صلبة أو طرية محتوية على sorbitol وsorbitan ، وأيضاً مثبط إنزيم reductase HMG-CoA. توفر صيغة الاختراع الحالي المشتمل على omega-3 fatty acid مكبسل مع sorbitol وsorbitan منع أفضل من أن يتم تكوين مواد متعلقة، مما يؤدي إلى ثبات تخزين طويل المدى محسن. يمكن أن ترفع الصيغة المعقدة عن طريق الفم oral للاختراع الحالي أيضاً مستوى المصل cholesterol - HDL، مع خفض كلا مستويي cholesterol - LDL وTG. تكون الصيغة المعقدة عن طريق الفم oral للاختراع الحالي مفيدة لعلاج فرط دهن الدم. شكل 1
SA112340005A 2011-11-17 2012-11-17 صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa SA112340005B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110120493 2011-11-17
KR1020120128926A KR101466617B1 (ko) 2011-11-17 2012-11-14 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제

Publications (1)

Publication Number Publication Date
SA112340005B1 true SA112340005B1 (ar) 2015-07-09

Family

ID=48663604

Family Applications (1)

Application Number Title Priority Date Filing Date
SA112340005A SA112340005B1 (ar) 2011-11-17 2012-11-17 صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa

Country Status (11)

Country Link
US (1) US20140314844A1 (ar)
EP (1) EP2780002A4 (ar)
JP (1) JP6073352B2 (ar)
KR (1) KR101466617B1 (ar)
CN (1) CN103957896A (ar)
AR (1) AR088876A1 (ar)
HK (1) HK1199396A1 (ar)
SA (1) SA112340005B1 (ar)
TW (1) TW201328727A (ar)
UY (1) UY34455A (ar)
WO (1) WO2013073884A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024844A1 (ko) * 2014-08-13 2016-02-18 한국유나이티드제약 주식회사 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제
TWI525110B (zh) * 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
KR102108154B1 (ko) * 2017-02-08 2020-05-07 (주)동구바이오제약 개선된 생체이용률을 갖는 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3307353C2 (de) * 1983-03-02 1985-01-31 R.P. Scherer GmbH, 6930 Eberbach Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US4963385A (en) * 1989-06-02 1990-10-16 Nabisco Brands, Inc. Stabilized emulsions containing highly unsaturated oils
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
WO2006062748A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
JP5628480B2 (ja) * 2006-03-09 2014-11-19 グラクソスミスクライン エルエルシー 医薬成分を含有するコーティングカプセル
AU2007258941B2 (en) * 2006-06-16 2013-08-01 Cipla Limited Improved dry powder inhaler
ITFI20060162A1 (it) * 2006-06-26 2007-12-27 Valpharma Sa Composizione farmaceutica per la somministrazione orale di acidi grassi omega polienoici ed uno o piu' principi attivi con essi incompatibili, e processo per la sua preparazione.
WO2008000731A2 (en) 2006-06-26 2008-01-03 Valpharma S.A. Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
US20100285121A1 (en) * 2008-01-10 2010-11-11 Takeda Pharmaceutical Company Limited Capsule Formulation
WO2009127974A2 (ko) * 2008-02-22 2009-10-22 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
US8933255B2 (en) * 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
JP5313343B2 (ja) * 2009-05-22 2013-10-09 持田製薬株式会社 ω３脂肪酸の自己乳化組成物

Also Published As

Publication number Publication date
AR088876A1 (es) 2014-07-16
UY34455A (es) 2013-06-28
HK1199396A1 (en) 2015-07-03
WO2013073884A1 (en) 2013-05-23
CN103957896A (zh) 2014-07-30
KR20130054921A (ko) 2013-05-27
US20140314844A1 (en) 2014-10-23
KR101466617B1 (ko) 2014-11-28
EP2780002A4 (en) 2015-05-27
JP2014533685A (ja) 2014-12-15
JP6073352B2 (ja) 2017-02-01
EP2780002A1 (en) 2014-09-24
TW201328727A (zh) 2013-07-16

Similar Documents

Publication Publication Date Title
UA106457C2 (ru) Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
MX2019010602A (es) Inhibidores de cdk.
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
MY184914A (en) Methods of administering pirfenidone theraphy
IN2014DN09370A (ar)
SI2576580T1 (sl) Znižanje nivoja laktata in zvišanje produkcije polipeptida z znižanjem ravni izražanja laktat-dehidrogenaze in piruvat-dehidrogenaza-kinaze
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2013MN00501A (ar)
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2013007436A (es) Uso de estabilizadores de glutamina.
MX340033B (es) Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
MX2015008135A (es) Composiciones para evitar olores que incluye microorganismos inodoros.
SA112340005B1 (ar) صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa
MY167897A (en) A compound separated from monascus-fermented rice, the preparation method and uses thereof
MD20160001A2 (ro) Utilizarea unei formulări orale pentru tratamentul bolilor cardiovasculare
WO2011093828A3 (en) Solid dosage forms comprising cefprozil
WO2011002161A3 (en) Transdermal composition comprising tolterodine
EP2727591A3 (en) Stable pharmaceutical compositions containing cefaclor and clavulanic acid
WO2012083408A8 (pt) Composições farmacêuticas antimaláricas contendo derivados de diterpenos caurânicos
WO2010129505A3 (en) Napthylene inhibitors of cyclooxygenase